Monte Rosa Therapeutics (GLUE) grants equity awards to accounting chief
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Monte Rosa Therapeutics, Inc. Principal Accounting Officer Matthew Bowen received new equity awards. He was granted a stock option covering 19,500 shares of common stock at an exercise price of $16.93 per share, expiring on April 5, 2036. Separately, he received 4,300 restricted stock units, each representing one share upon vesting. The RSUs vest 25% on April 6, 2027, with the remainder in three equal annual installments, while the option vests 25% on April 6, 2027 and then in 36 substantially equal monthly installments, in each case subject to continued service. Following the RSU grant, he directly owns 25,904 shares of common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Bowen Matthew
Role
Principal Accounting Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 19,500 | $0.00 | -- |
| Grant/Award | Common Stock | 4,300 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 19,500 shares (Direct);
Common Stock — 25,904 shares (Direct)
Footnotes (1)
- Represents restricted stock units ("RSUs") granted under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 25% of the RSUs shall vest on April 6, 2027, with the remainder vesting in 3 equal annual installments thereafter, subject to the Reporting Person's continued service on each such vesting date. 25% of this option shall vest and become exercisable on April 6, 2027, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
Key Figures
Option grant size: 19,500 shares
Option exercise price: $16.93 per share
Option expiration: April 5, 2036
+3 more
6 metrics
Option grant size
19,500 shares
Stock Option (Right to Buy) granted April 6, 2026
Option exercise price
$16.93 per share
Exercise price for 19,500-share option
Option expiration
April 5, 2036
Expiration date of stock option grant
RSU grant size
4,300 units
Restricted stock units granted April 6, 2026
Initial vesting date
April 6, 2027
25% of RSUs and 25% of option vest on this date
Common shares after grant
25,904 shares
Total common stock held directly after RSU acquisition
Key Terms
restricted stock units ("RSUs"), 2021 Stock Option and Incentive Plan, Stock Option (Right to Buy), vesting
4 terms
restricted stock units ("RSUs") financial
"Represents restricted stock units ("RSUs") granted under the Issuer's 2021 Stock Option and Incentive Plan."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
2021 Stock Option and Incentive Plan financial
"RSUs granted under the Issuer's 2021 Stock Option and Incentive Plan."
Stock Option (Right to Buy) financial
"security_title": "Stock Option (Right to Buy)""
vesting financial
"25% of the RSUs shall vest on April 6, 2027, with the remainder vesting in 3 equal annual installments thereafter"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
What equity awards did GLUE executive Matthew Bowen receive?
Matthew Bowen received a stock option for 19,500 shares and 4,300 restricted stock units. The option has a $16.93 exercise price, and both awards vest over multiple years, subject to his continued service with Monte Rosa Therapeutics.
How do the new stock options for GLUE’s Matthew Bowen vest?
The 19,500-share stock option vests 25% on April 6, 2027, with the remaining 75% vesting in 36 substantially equal monthly installments. Vesting is conditioned on Matthew Bowen’s continued service on each applicable vesting date.
What is the vesting schedule for Matthew Bowen’s GLUE RSU grant?
The 4,300 restricted stock units vest 25% on April 6, 2027, with the remaining 75% vesting in three equal annual installments thereafter. Each vested RSU settles into one share of Monte Rosa Therapeutics common stock, subject to continued service.
What is the exercise price and expiration date of GLUE’s new option grant?
The stock option granted to Matthew Bowen has an exercise price of $16.93 per share and an expiration date of April 5, 2036. It represents a right to buy Monte Rosa Therapeutics common stock once vested and exercised.